Global Autoimmune Disease Therapeutics Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

Section 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research

1.5. Analyst tools and models

Section 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

Section 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Market dynamics

3.3.1. Drivers

3.3.1.1. Surge in adoption of autoimmune disease therapeutics
3.3.1.2. Increase in incidence of autoimmune disease
3.3.1.3. Wide availability of advanced therapeutics

3.3.2. Restraints

3.3.2.1. Higher cost associated with advanced autoimmune disease therapeutics

3.3.3. Opportunity

3.3.3.1. Growth opportunities in emerging economies
3.3.3.2. Strong presence of pipeline drugs

3.4. Top player positioning, 2017

Section 4: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Anti-inflammatory

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country

4.3. Antihyperglycemics

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country

4.4. NSAIDs

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

4.5. Interferons

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country

4.6. Others

4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast
4.6.3. Market analysis, by country

Section 5: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY INDICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Rheumatic disease

5.2.1. Key market trends, growth factors, and opportunities
5.2.2. Market size and forecast
5.2.3. Market analysis, by country

5.3. Type 1 Diabetes

5.3.1. Key market trends, growth factors, and opportunities
5.3.2. Market size and forecast
5.3.3. Market analysis, by country

5.4. Multiple sclerosis

5.4.1. Key market trends, growth factors, and opportunities
5.4.2. Market size and forecast
5.4.3. Market analysis, by country

5.5. Inflammatory Bowel Disease

5.5.1. Key market trends, growth factors, and opportunities
5.5.2. Market size and forecast
5.5.3. Market analysis, by country

5.6. Other indications

5.6.1. Key market trends, growth factors, and opportunities
5.6.2. Market size and forecast
5.6.3. Market analysis, by country

Section 6: AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY SALES CHANNEL

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospital pharmacy

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Online providers

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Drug stores & retail pharmacies

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

Section 7: GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends and opportunities

7.2.1.1. US

7.2.1.1.1. Market size and forecast, by Drug Class
7.2.1.1.2. Market size and forecast, by Indication
7.2.1.1.3. Market size and forecast, by Sales Channel

7.2.1.2. Canada

7.2.1.2.1. Market size and forecast, by Drug Class
7.2.1.2.2. Market size and forecast, by Indication
7.2.1.2.4. Market size and forecast, by Sales Channel

7.2.1.3. Mexico

7.2.1.3.1. Market size and forecast, by Drug Class
7.2.1.3.2. Market size and forecast, by Indication
7.2.1.3.4. Market size and forecast, by Sales Channel

7.2.2. North America Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.2.3. North America Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.2.4. North America Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.2.5. North America Autoimmune Disease Therapeutics Market size and forecast, by region

7.3. Europe

7.3.1. Key market trends and opportunities

7.3.1.1. Germany

7.3.1.1.1. Market size and forecast, by Drug Class
7.3.1.1.2. Market size and forecast, by Indication
7.3.1.1.3. Market size and forecast, by Sales Channel

7.3.1.2. France

7.3.1.2.1. Market size and forecast, by Drug Class
7.3.1.2.2. Market size and forecast, by Indication
7.3.1.2.4. Market size and forecast, by Sales Channel

7.3.1.3. UK

7.3.1.3.1. Market size and forecast, by Drug Class
7.3.1.3.2. Market size and forecast, by Indication
7.3.1.3.4. Market size and forecast, by Sales Channel

7.3.1.4. Italy

7.3.1.4.1. Market size and forecast, by Drug Class
7.3.1.4.2. Market size and forecast, by Indication
7.3.1.4.4. Market size and forecast, by Sales Channel

7.3.1.5. Spain

7.3.1.5.1. Market size and forecast, by Drug Class
7.3.1.5.2. Market size and forecast, by Indication
7.3.1.5.3. Market size and forecast, by Sales Channel

7.3.1.6. Rest of Europe

7.3.1.6.1. Market size and forecast, by Drug Class
7.3.1.6.2. Market size and forecast, by Indication
7.3.1.6.3. Market size and forecast, by Sales Channel

7.3.2. Europe Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.3.3. Europe Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.3.4. Europe Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.3.5. Europe Autoimmune Disease Therapeutics Market size and forecast, by region

7.4. Asia-Pacific

7.4.1. Key market trends and opportunities

7.4.1.1. Japan

7.4.1.1.1. Market size and forecast, by Drug Class
7.4.1.1.2. Market size and forecast, by Indication
7.4.1.1.4. Market size and forecast, by Sales Channel

7.4.1.2. China

7.4.1.2.1. Market size and forecast, by Drug Class
7.4.1.2.2. Market size and forecast, by Indication
7.4.1.2.3. Market size and forecast, by Sales Channel

7.4.1.3. Australia

7.4.1.3.1. Market size and forecast, by Drug Class
7.4.1.3.2. Market size and forecast, by Indication
7.4.1.3.4. Market size and forecast, by Sales Channel

7.4.1.4. India

7.4.1.4.1. Market size and forecast, by Drug Class
7.4.1.4.2. Market size and forecast, by Indication
7.4.1.4.4. Market size and forecast, by Sales Channel

7.4.1.5. South Korea

7.4.1.5.1. Market size and forecast, by Drug Class
7.4.1.5.2. Market size and forecast, by Indication
7.4.1.5.3. Market size and forecast, by Sales Channel

7.4.1.6. Rest of Asia-Pacific

7.4.1.6.1. Market size and forecast, by Drug Class
7.4.1.6.2. Market size and forecast, by Indication
7.4.1.6.3. Market size and forecast, by Sales Channel

7.4.2. Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.4.3. Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.4.5. Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.4.6. Asia-Pacific Autoimmune Disease Therapeutics Market size and forecast, by region

7.5. LAMEA

7.5.1. Key market trends and opportunities

7.5.1.1. Brazil

7.5.1.1.1. Market size and forecast, by Drug Class
7.5.1.1.2. Market size and forecast, by Indication
7.5.1.1.4. Market size and forecast, by Sales Channel

7.5.1.2. Saudi Arabia

7.5.1.2.1. Market size and forecast, by Drug Class
7.5.1.2.2. Market size and forecast, by Indication
7.5.1.2.3. Market size and forecast, by Sales Channel

7.5.1.3. South Africa

7.5.1.3.1. Market size and forecast, by Drug Class
7.5.1.3.2. Market size and forecast, by Indication
7.5.1.3.4. Market size and forecast, by Sales Channel

7.5.1.4. Rest of LAMEA

7.5.1.4.1. Market size and forecast, by Drug Class
7.5.1.4.2. Market size and forecast, by Indication
7.5.1.4.3. Market size and forecast, by Sales Channel

7.5.2. LAMEA Autoimmune Disease Therapeutics Market size and forecast, by Drug Class
7.5.3. LAMEA Autoimmune Disease Therapeutics Market size and forecast, by Indication
7.5.5. LAMEA Autoimmune Disease Therapeutics Market size and forecast, by Sales Channel
7.5.6. LAMEA Autoimmune Disease Therapeutics Market size and forecast, by region

Section 8: COMPANY PROFILES

8.1. Abbott Laboratories

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.1.5. Business performance

8.2. AbbVie Inc.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. Amgen Inc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. AstraZeneca Plc.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance

8.5. Bristol-Myers Squibb Company

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance

8.7. Johnson & Johnson

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. Novartis AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance

8.9. Pfizer Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product Portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. UCB S.A.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Product Portfolio
8.10.4. Business performance
8.10.5. Key strategic moves and developments